Clinical Trial Update: Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating RP-6306 in combination with carboplatin and paclitaxel for TP53-mutant recurrent ovarian and uterine cancers; the trial status is activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Uterine Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• RP-6306

Snippet

Sponsor: University Health Network, Toronto | Conditions: Recurrent Ovarian Cancer, Recurrent Uterine Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING